Novartis has announced plans to add a new facility in Morrisville, North Carolina, focused on active pharmaceutical ingredient (API) manufacturing for solid dosage tablets, capsules and RNA therapeutics—the company’s seventh new facility planned within a year of its announced $23 billion investment in U.S.-based manufacturing, research and development. The 56,200-square-foot facility will strengthen end‑to‑end U.S. production capability from active ingredients through finished medicines and e...